Flora Peyvandi Selected Research

Type 3 von Willebrand Disease

1/2022	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
10/2021	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.
1/2020	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
9/2012	Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients.
5/2003	Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Flora Peyvandi Research Topics

Disease

66	Hemorrhage 03/2022 - 05/2002
57	Hemophilia A (Haemophilia) 03/2022 - 05/2002
34	Thrombotic Thrombocytopenic Purpura 01/2022 - 04/2003
21	Thrombosis (Thrombus) 01/2022 - 09/2005
17	COVID-19 08/2022 - 01/2020
17	Afibrinogenemia (Fibrinogen Deficiency) 01/2022 - 08/2002
14	acquired Thrombotic thrombocytopenic purpura 01/2021 - 08/2005
13	von Willebrand Diseases (von Willebrand's Disease) 12/2022 - 07/2011
11	Thrombocytopenia (Thrombopenia) 08/2022 - 11/2004
11	Thrombotic Microangiopathies 01/2021 - 04/2003
8	Thrombophilia 01/2022 - 07/2005
8	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 02/2012
7	Myocardial Infarction 01/2016 - 08/2006
6	Infections 08/2022 - 01/2007
6	Stroke (Strokes) 01/2020 - 02/2010
6	Coronary Artery Disease (Coronary Atherosclerosis) 10/2016 - 04/2009
5	Pneumonia (Pneumonitis) 05/2022 - 08/2013
5	Inflammation (Inflammations) 01/2022 - 02/2016
5	Fibrosis (Cirrhosis) 01/2022 - 07/2014
5	Type 3 von Willebrand Disease 01/2022 - 05/2003
5	Hemolytic Anemia 01/2019 - 11/2004
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2015
4	Venous Thromboembolism 01/2021 - 08/2013
4	Hypertension (High Blood Pressure) 01/2021 - 04/2016
4	Genetic Predisposition to Disease (Genetic Predisposition) 10/2020 - 08/2010
4	Inherited Blood Coagulation Disorders 02/2019 - 09/2004
3	Respiratory Insufficiency (Respiratory Failure) 06/2022 - 10/2020
3	Sepsis (Septicemia) 05/2022 - 02/2010
3	Joint Diseases (Joint Disease) 03/2022 - 09/2018
3	Hemarthrosis 03/2022 - 01/2020
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 08/2007
3	Spontaneous Abortion (Miscarriage) 04/2020 - 11/2014
3	Menorrhagia 01/2020 - 07/2009
3	Liver Diseases (Liver Disease) 01/2020 - 09/2018
3	Hemophilia B (Haemophilia B) 01/2020 - 05/2015
3	Ischemic Stroke 01/2016 - 08/2010
3	Familial Multiple Coagulation Factor Deficiency I 06/2009 - 08/2005
3	Factor V Deficiency 10/2008 - 01/2003
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 08/2022 - 08/2005
2	Chronic Pain 03/2022 - 01/2021
2	Type 1 von Willebrand Disease 03/2022 - 01/2021
2	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2014
2	Drug-Related Side Effects and Adverse Reactions 10/2021 - 02/2018
2	Hypersensitivity (Allergy) 09/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

38	Factor VIII (Coagulation Factor VIII)IBA 01/2022 - 05/2002
32	thiamine triphosphorate (TTP)IBA 11/2020 - 04/2003
29	von Willebrand FactorIBA 12/2022 - 04/2003
26	Fibrinogen (Factor I)FDA Link 01/2022 - 08/2002
18	Blood Coagulation Factors (Coagulation Factor)IBA 03/2022 - 10/2002
13	Thrombin FDA Link 01/2022 - 10/2002
12	AntibodiesIBA 06/2022 - 08/2005
11	AutoantibodiesIBA 01/2022 - 11/2004
11	Factor V (Coagulation Factor V)IBA 11/2019 - 10/2002
10	emicizumabIBA 09/2021 - 01/2019
9	AnticoagulantsIBA 01/2022 - 12/2012
9	Hemostatics (Antihemorrhagics)IBA 01/2021 - 02/2012
9	Metalloproteases (Metalloproteinases)IBA 10/2020 - 08/2005
8	AntigensIBA 03/2020 - 04/2003
7	Proteins (Proteins, Gene)FDA Link 02/2021 - 08/2005
7	DisintegrinsIBA 10/2020 - 08/2005
7	ThrombospondinsIBA 10/2020 - 08/2005
7	Factor X (Stuart Factor)IBA 01/2020 - 10/2002
6	Biomarkers (Surrogate Marker)IBA 06/2022 - 02/2008
6	ADAMTS13 ProteinIBA 01/2019 - 04/2003
5	Complement System Proteins (Complement)IBA 11/2021 - 11/2012
5	Monoclonal AntibodiesIBA 09/2021 - 12/2016
5	caplacizumabIBA 01/2021 - 01/2016
5	Prothrombin (Factor II)IBA 01/2019 - 08/2002
5	Vitamin K FDA Link 01/2018 - 06/2009
5	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 07/2005
4	Immunoglobulin G (IgG)IBA 06/2022 - 08/2005
4	BESIBA 01/2022 - 01/2018
4	VaccinesIBA 01/2022 - 10/2021
4	NucleotidesIBA 01/2021 - 01/2016
4	CoagulantsIBA 01/2021 - 07/2012
4	RivaroxabanIBA 01/2021 - 11/2013
4	EnzymesIBA 11/2019 - 08/2005
4	Pharmaceutical PreparationsIBA 09/2018 - 10/2012
4	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2017 - 05/2002
4	Factor VII (Proconvertin)IBA 07/2011 - 10/2002
3	FibrinIBA 01/2022 - 10/2016
3	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2020
3	C-Reactive ProteinIBA 11/2021 - 02/2021
3	COVID-19 VaccinesIBA 10/2021 - 01/2021
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 10/2016
3	Neutralizing AntibodiesIBA 01/2017 - 01/2016
3	Dronabinol (THC)FDA LinkGeneric 10/2016 - 01/2015
3	omega-Chloroacetophenone (Mace)IBA 10/2016 - 01/2015
3	Protein CIBA 07/2014 - 08/2013
3	Peptide Hydrolases (Proteases)FDA Link 02/2008 - 04/2003
3	BBeta fibrinogenIBA 10/2003 - 08/2002
2	Oxygen (Dioxygen)IBA 06/2022 - 02/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 01/2020
2	Rituximab (Mabthera)FDA Link 01/2022 - 01/2018
2	recombinant FVIIa (rFVIIa)FDA Link 01/2022 - 07/2018
2	ElementsIBA 10/2021 - 01/2018
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2021 - 01/2021
2	Messenger RNA (mRNA)IBA 09/2021 - 09/2012

Therapy/Procedure

40	Therapeutics 06/2022 - 12/2008
3	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/2016 - 01/2013